WO1999055715A3 - Polysaccharide-antigen conjugates - Google Patents

Polysaccharide-antigen conjugates Download PDF

Info

Publication number
WO1999055715A3
WO1999055715A3 PCT/US1999/009164 US9909164W WO9955715A3 WO 1999055715 A3 WO1999055715 A3 WO 1999055715A3 US 9909164 W US9909164 W US 9909164W WO 9955715 A3 WO9955715 A3 WO 9955715A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
polysaccharide
antigen
disclosed
methods
Prior art date
Application number
PCT/US1999/009164
Other languages
French (fr)
Other versions
WO1999055715A2 (en
Inventor
Dante J Marciani
Original Assignee
Galenica Pharmaceuticals Inc
Dante J Marciani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galenica Pharmaceuticals Inc, Dante J Marciani filed Critical Galenica Pharmaceuticals Inc
Priority to AU37676/99A priority Critical patent/AU760669B2/en
Priority to CA002329897A priority patent/CA2329897A1/en
Priority to JP2000545873A priority patent/JP2002513028A/en
Priority to EP99920096A priority patent/EP1073667A2/en
Publication of WO1999055715A2 publication Critical patent/WO1999055715A2/en
Publication of WO1999055715A3 publication Critical patent/WO1999055715A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Abstract

The present invention is directed to chemical conjugates (herein referred to as polysaccharide adjuvant-antigen conjugates) that have a polysaccharide backbone capable of binding to the cell surface of Antigen Presenting Cells (APCs), to which is covalently attached (a) one or more molecules having a stable carbonyl group (i.e. an aldehyde and ketone group that is capable of reacting with amino groups to form an imine or Schiff base), and (b) one or more polypeptides or peptides that are capable of eliciting an immunogenic response when covalently attached to polysaccharide backbone. Also disclosed are methods for making the conjugates and methods of using the conjugates to enhance the potentiation of an immune response in a mammal. Also disclosed is a method of vaccination, and pharmaceutical and veterinary compositions comprising one or more of the polysaccharide adjuvant-antigen conjugates of the present invention.
PCT/US1999/009164 1998-04-28 1999-04-28 Polysaccharide-antigen conjugates WO1999055715A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU37676/99A AU760669B2 (en) 1998-04-28 1999-04-28 Polysaccharide-antigen conjugates
CA002329897A CA2329897A1 (en) 1998-04-28 1999-04-28 Polysaccharide-antigen conjugates
JP2000545873A JP2002513028A (en) 1998-04-28 1999-04-28 Polysaccharide antigen conjugate
EP99920096A EP1073667A2 (en) 1998-04-28 1999-04-28 Polysaccharide-antigen conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8310698P 1998-04-28 1998-04-28
US60/083,106 1998-04-28

Publications (2)

Publication Number Publication Date
WO1999055715A2 WO1999055715A2 (en) 1999-11-04
WO1999055715A3 true WO1999055715A3 (en) 1999-12-29

Family

ID=22176213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009164 WO1999055715A2 (en) 1998-04-28 1999-04-28 Polysaccharide-antigen conjugates

Country Status (6)

Country Link
US (1) US6573245B1 (en)
EP (1) EP1073667A2 (en)
JP (1) JP2002513028A (en)
AU (1) AU760669B2 (en)
CA (1) CA2329897A1 (en)
WO (1) WO1999055715A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9815388A (en) * 1997-10-03 2001-08-21 Galenica Pharmaceuticals Inc Imine-forming polysaccharides, their preparation and their use as adjuvants and immunostimulants
AU3879200A (en) * 1999-08-16 2001-03-13 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US6956119B2 (en) 2000-03-21 2005-10-18 Hans Loibner Polysaccharide-polypeptide conjugate
FR2807946B1 (en) * 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale NEEDLELESS SYRINGE OPERATING WITH A TWO-COMPOSITION PYROTECHNIC LOAD
AU2001263653B2 (en) * 2000-06-06 2006-06-29 Igavax Pty Ltd Vaccine
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
AU2003299863B2 (en) * 2002-08-15 2009-09-24 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
ES2781848T3 (en) * 2003-10-24 2020-09-08 Nutricia Nv Immunomodulatory oligosaccharides
US20050220846A1 (en) 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
JP2006028075A (en) * 2004-07-15 2006-02-02 Sanrihama Tokusan Nogyo Kyodo Kumiai Phosphorylated fructan and method for preparing the same
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
ATE516816T1 (en) 2005-06-27 2011-08-15 Glaxosmithkline Biolog Sa METHOD FOR PRODUCING VACCINES
DK1928503T3 (en) 2005-08-24 2012-10-15 Immunogen Inc Process for Preparation of Purified Drug Conjugates
JP5683069B2 (en) * 2005-10-27 2015-03-11 バイオ−ラッド・ハイファ・リミテッド Binding layer and method for its preparation and use thereof
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US8420607B2 (en) * 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
CA2656606A1 (en) 2006-06-30 2008-09-25 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates,synthesis and uses thereof
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
CN101896197B (en) * 2007-09-11 2013-10-23 圭尔夫大学 Polysaccharide immunogens from clostridium difficile
WO2009117572A1 (en) * 2008-03-19 2009-09-24 Wisconsin Alumni Research Foundation Production of protein-polysaccharide conjugates
WO2010104747A2 (en) * 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
AU2010222928B2 (en) * 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
CN103816870B (en) 2008-12-03 2016-11-23 株式会社钟化 Porous carrier containing formoxyl, the adsorbate using this porous carrier and their manufacture method
US8629121B2 (en) * 2009-01-27 2014-01-14 World Force Technologies, Llc High molecular weight polysaccharide that binds and inhibits virus
CA2754862C (en) 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
MX349210B (en) 2009-06-03 2017-07-18 Immunogen Inc Conjugation methods.
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
BR112012028893A2 (en) 2010-05-10 2017-12-12 Ascend Biopharmaceuticals Pty Ltd immunostimulatory and vaccine compositions
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
KR20220123130A (en) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 Preparation of maytansinoid antibody conjugates by a one-step process
US20140228543A1 (en) * 2011-05-06 2014-08-14 Biothera, Inc. MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
EP2934596A1 (en) * 2012-12-21 2015-10-28 Glykos Finland Oy Linker-payload molecule conjugates
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
EP3110437B1 (en) 2014-02-12 2017-11-29 Omnigen Research, LLC Composition and method for promoting reduction of heat stress in animals
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
EP3655466A4 (en) * 2017-07-20 2021-05-12 Xinova, LLC Stabilized biofiller particles and polymer compositions including the same
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
MX2022013456A (en) * 2020-05-01 2022-11-16 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen.
CN116113644A (en) * 2020-09-14 2023-05-12 神州细胞工程有限公司 Method for enhancing immunogenicity by saccharide-coronavirus RBD antigen conjugates
WO2022192655A1 (en) * 2021-03-12 2022-09-15 Children's Medical Center Corporation Polysaccharide adjuvants for virus vaccines
WO2023230241A1 (en) * 2022-05-27 2023-11-30 Design-Zyme LLC Universal adjuvant for nasal, oral, and intramuscular delivery of vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
WO1996040225A1 (en) * 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
WO1997033612A1 (en) * 1996-03-15 1997-09-18 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO1999017783A1 (en) * 1997-10-03 1999-04-15 Galenica Pharmaceuticals, Inc. Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236792A (en) 1963-12-12 1966-02-22 Miles Lab Water-dispersible form of dialdehyde polysaccharides and process therefor
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US4063016A (en) 1975-12-15 1977-12-13 University Of Delaware Chitin complexes with alcohols and carbonyl compounds
US4424346A (en) 1981-06-04 1984-01-03 Canadian Patents And Development Ltd. Derivatives of chitins, chitosans and other polysaccharides
SE8200751L (en) 1982-02-09 1983-08-10 Olle Larm PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS
DE3340592A1 (en) 1983-11-10 1985-05-23 B. Braun Melsungen Ag, 3508 Melsungen CONJUGATES OF MACROMOLECULAR COMPOUNDS TO HAEMOGLOBINE, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THE SAME
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4693891A (en) 1985-09-09 1987-09-15 Miles Laboratories, Inc. Vaccine for Pseudomonas aeruginosa
DK163176C (en) 1985-09-27 1992-06-22 Schweiz Serum & Impfinst POISONOUS CONJUGATE VACCINE AGAINST INFECTIONS OF PSEUDOMONA'S AERUGINOSA AND ESCHERICHIA COLI BACTERIES, METHOD OF PRODUCING IT AND USING THE VACCINE
US4734362A (en) 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
EP0320942A3 (en) 1987-12-18 1989-10-04 American Cyanamid Company Novel polysaccharides novel macromolecular conjugates of the polysaccharides
EP0326111A3 (en) 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
FR2630329B1 (en) 1988-04-20 1991-07-05 Merieux Inst MACROMOLECULAR CONJUGATES OF HEMOGLOBIN, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
US5057503A (en) 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5169840A (en) 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Peptide-carbohydrate conjugates capable of generating t cell immunity
SE500964C2 (en) 1993-01-19 1994-10-10 Medicarb Ab Solid surface modified carrier wherein the modification is effected by a primer containing a polysaccharide and process for producing such a carrier
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5567685A (en) 1994-08-16 1996-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Water-Soluble polyene conjugate
WO1996020012A2 (en) 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Methods for preparing and purifying macromolecular conjugates
JP3929491B2 (en) 1995-04-04 2007-06-13 ウーンド・ヒーリング・オブ・オクラホマ・インコーポレーテッド Cancer treatment by photodynamic therapy combined with immunoadjuvant
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
WO1996040225A1 (en) * 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
WO1997033612A1 (en) * 1996-03-15 1997-09-18 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO1999017783A1 (en) * 1997-10-03 1999-04-15 Galenica Pharmaceuticals, Inc. Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOOD A H ET AL: "IDENTIFICATION OF CARBOHYDRATE STRUCTURES THAT BIND HUMAN ANTIPORCINE ANTIBODIES: IMPLICATIONS FOR DISCORDANT XENOGRAFTING INHUMANS", TRANSPLANTATION PROCEEDINGS, vol. 24, no. 2, April 1992 (1992-04-01), pages 559 - 562, XP002916011, ISSN: 0041-1345 *
KOLAR C ET AL: "PREPARATION AND USE OF SYNTHETIC BLOOD GROUP SPECIFIC IMMUNOADSORBENTS", BEHRING INSTITUTE: MITTEILUNGEN, vol. 82, 1988, pages 94 - 103, XP002916010 *
STAHL P D: "THE MANNOSE RECEPTOR AND OTHER MACROPHAGE LECTINS", CURRENT OPINION IN IMMUNOLOGY, vol. 4, no. 1, 1 February 1992 (1992-02-01), pages 49 - 52, XP000647872, ISSN: 0952-7915 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US9526702B2 (en) 2007-10-12 2016-12-27 Massachusetts Institute Of Technology Vaccine nanotechnology

Also Published As

Publication number Publication date
WO1999055715A2 (en) 1999-11-04
US6573245B1 (en) 2003-06-03
JP2002513028A (en) 2002-05-08
EP1073667A2 (en) 2001-02-07
CA2329897A1 (en) 1999-11-04
AU3767699A (en) 1999-11-16
AU760669B2 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
WO1999055715A3 (en) Polysaccharide-antigen conjugates
WO2002005146A3 (en) Method for disigning protein libraries with altered immunogenicity
EP1847549A3 (en) Papillomavirus polyprotein constructs
WO2001096368A3 (en) Use of coiled-coil structural scaffold to generate structure-specific peptides
Glaffig et al. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer
WO2000054802A3 (en) Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization
WO2004030617A3 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
NO20062765L (en) Immunogenic peptide-bearing conjugates and processes for their preparation
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
NZ506086A (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins, antigens comprising derivatised thiol residues and of compositions for vaccination
EP1862472A3 (en) Chlamydia protein, gene sequence and uses thereof
ATE389397T1 (en) ADJUVANT COMPOSITIONS
WO2006096497A3 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO1998047530A3 (en) Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
AU2715302A (en) Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
WO1996040792A1 (en) Modification of polypeptides
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
Mezö et al. Synthesis and Comparison of Antibody Recognition of Conjugates Containing Herpes Simplex Virus Type 1 Glycoprotein D Epitope VII1
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
WO2000063385A3 (en) Nucleic acid immunization
CO5280140A1 (en) ANTIGEN (C42) ASSOCIATED WITH TUMORS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2329897

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 545873

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 37676/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999920096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999920096

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 37676/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999920096

Country of ref document: EP